Angiodynamics Inc Sample Contracts

Angiodynamics Inc – PRESS RELEASE (October 3rd, 2019)
Angiodynamics Inc – NEWS RELEASE (October 3rd, 2019)

This transaction expands AngioDynamics’ existing Vascular Interventions and Therapies (VIT) product portfolio by adding Eximo’s proprietary laser technology, which has received 510(k) clearance for use in the treatment of Peripheral Artery Disease (PAD). The Eximo technology complements AngioDynamics’ leading thrombus management and venous insufficiency technologies.

Angiodynamics Inc – PRESS RELEASE (July 10th, 2019)
Angiodynamics Inc – Notice Regarding Forward-Looking StatementsThis presentation contains forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “es (July 10th, 2019)
Angiodynamics Inc – NEWS RELEASE (June 6th, 2019)

Latham, New York, June 3, 2019 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC® fluid management portfolio to Medline Industries, Inc. on May 31, 2019 for $167.5 million.

Angiodynamics Inc – CREDIT AGREEMENT (June 6th, 2019)

CREDIT AGREEMENT (this “Agreement”) dated as of June 3, 2019 among ANGIODYNAMICS, INC., the LENDERS from time to time party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

Angiodynamics Inc – AngioDynamics, Inc. and Subsidiaries (June 6th, 2019)

The Company’s historical consolidated financial statements have been adjusted in the unaudited consolidated pro forma financial statements to present events that are (i) directly attributable to the Transaction, (ii) factually supportable and (iii) are expected to have a continuing impact on the Company’s consolidated results following the Transaction. The allocation of corporate support, general, management and administrative and other liabilities and expenses included may differ from expenses that would have been included on a stand-alone basis. The pro forma consolidated statements of net income do not reflect the estimated gain on the Transaction.

Angiodynamics Inc – Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans (April 18th, 2019)
Angiodynamics Inc – NEWS RELEASE (April 18th, 2019)

AngioDynamics, Inc. Michael Greiner 518-795-1821 mgreiner@angiodynamics.com AngioDynamics, Inc. Saleem Cheeks 518-795-1174 scheeks@angiodynamics.com Medline Blair Klein 847-643-3308 bklein@medline.com

Angiodynamics Inc – ASSET PURCHASE AGREEMENT dated as of April 17, 2019 by and between ANGIODYNAMICS, INC. and MEDLINE INDUSTRIES, INC. (April 18th, 2019)
Angiodynamics Inc – Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans (April 2nd, 2019)
Angiodynamics Inc – PRESS RELEASE (April 2nd, 2019)
Angiodynamics Inc – PRESS RELEASE (January 4th, 2019)
Angiodynamics Inc – Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans (January 4th, 2019)
Angiodynamics Inc – PRESS RELEASE (September 27th, 2018)
Angiodynamics Inc – Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “be (September 6th, 2018)
Angiodynamics Inc – PERFORMANCE UNIT AWARD AGREEMENT (July 23rd, 2018)

This Performance Unit Award Agreement (this “Agreement”), dated as of the 18th day of July, 2018 (the “Grant Date”), is between AngioDynamics, Inc., a Delaware corporation (the “Company”), and the (“Participant”), an employee of the Company or any of its affiliates or subsidiaries and whose name appears on the signature page hereto. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the AngioDynamics 2004 Stock and Incentive Award Plan, as amended (the “Plan”) or in the Total Shareholder Return Performance Unit Award Program (the “Program”) for the performance period calculated pursuant to the Program (the “Performance Period”).

Angiodynamics Inc – EXECUTION COPY AMENDMENT NO. 1 Dated as of May 24, 2018 to CREDIT AGREEMENT Dated as of November 7, 2016 THIS AMENDMENT NO. 1 (this “Amendment”) is made as of May 24, 2018 by and among AngioDynamics, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Credit Agreement dated as of November 7, 2016 by and among the Borrower, the Lenders and the Administrative Agent (as amended, restated, supplemented or otherwise modified from time to (July 23rd, 2018)
Angiodynamics Inc – Total Shareholder Return Performance Unit Award Program (the “Program”) Performance Period July 12, 2018 – July, 2021 (July 23rd, 2018)
Angiodynamics Inc – NON‑STATUTORY STOCK OPTION AGREEMENT (July 23rd, 2018)

THIS AGREEMENT is made as of ________ between AngioDynamics, Inc., ("Company") and __________ ("Optionee"). Terms used herein have the same meaning as in the Company's 2004 Stock and Incentive Award Plan ("Plan").

Angiodynamics Inc – PRESS RELEASE (July 11th, 2018)
Angiodynamics Inc – PRESS RELEASE (March 29th, 2018)
Angiodynamics Inc – PRESS RELEASE (January 24th, 2018)

Latham, New York, January 24, 2018 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted the Expedited Access Pathway (EAP) designation to the Company’s NanoKnife System and proposed indication for use for the treatment of Stage III pancreatic cancer.

Angiodynamics Inc – PRESS RELEASE (January 4th, 2018)
Angiodynamics Inc – PERFORMANCE UNIT AWARD AGREEMENT (September 29th, 2017)

This Performance Unit Award Agreement (this “Agreement”), dated as of the 26th day of July, 2017 (the “Grant Date”), is between AngioDynamics, Inc., a Delaware corporation (the “Company”), and the (“Participant”), an employee of the Company or any of its affiliates or subsidiaries and whose name appears on the signature page hereto. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the AngioDynamics 2004 Stock and Incentive Award Plan, as amended (the “Plan”) or in the Total Shareholder Return Performance Unit Award Program (the “Program”) for the period beginning July 19, 2017 and ending on the date that is the second trading day following the Company’s annual earnings announcement for the fiscal year ending May 31, 2020 (the “Performance Period”).

Angiodynamics Inc – Total Shareholder Return Performance Unit Award Program (the “Program”) Performance Period July 19, 2017 - July, 2020 (September 29th, 2017)
Angiodynamics Inc – FOR IMMEDIATE DISTRIBUTION (September 28th, 2017)

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticonsulting.com, Kotaro Yoshida (212) 850-5690 Kotaro.Yoshida@fticonsulting.com FTI Consulting Kimberly Ha (212) 850-5612 kimberly.ha@fticonsulting.com

Angiodynamics Inc – FOR IMMEDIATE RELEASE (July 18th, 2017)

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticonsulting.com, Kotaro Yoshida (212) 850-5690 Kotaro.Yoshida@fticonsulting.com FTI Consulting Kimberly Ha (212) 850-5612 kimberly.ha@fticonsulting.com

Angiodynamics Inc – AngioDynamics, Inc. (April 12th, 2017)

The stockholders named in Schedule II hereto (the “Selling Stockholders”) of AngioDynamics, Inc., a Delaware corporation (the “Company”), propose, subject to the terms and conditions stated herein, to sell to Barclays Capital Inc. as set forth in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis) an aggregate of 2,350,000 shares (the “Shares”) of Common Stock, par value $0.01 (“Stock”) of the Company.

Angiodynamics Inc – FOR IMMEDIATE DISTRIBUTION (March 30th, 2017)

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticonsulting.com, Kotaro Yoshida (212) 850-5690 Kotaro.Yoshida@fticonsulting.com FTI Consulting Kimberly Ha (212) 850-5612 kimberly.ha@fticonsulting.com

Angiodynamics Inc – FOR IMMEDIATE RELEASE (January 6th, 2017)

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstafanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticonsulting.com, Kotaro Yoshida (212) 850-5690 Kotaro.Yoshida@fticonsulting.com FTI Consulting Kimberly Ha (212) 850-5612 kimberly.ha@fticonsulting.com

Angiodynamics Inc – Underwriting Agreement (November 18th, 2016)

The stockholders named in Schedule II hereto (the “Selling Stockholders”) of AngioDynamics, Inc., a Delaware corporation (the “Company”), propose, subject to the terms and conditions stated herein, to sell to Barclays Capital Inc. as set forth in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis) an aggregate of 2,500,000 shares (the “Shares”) of Common Stock, par value $0.01 (“Stock”) of the Company. Subject to the sale of the Shares by the Selling Stockholders to the Underwriters in compliance with the terms of this Agreement, the Underwriters have agreed to sell to the Company, and the Company has agreed herein to purchase from the Underwriters (the “Share Repurchase”), an aggregate of 500,000 shares of the Shares (the “Repurchase Shares”) pursuan

Angiodynamics Inc – AngioDynamics Announces New Senior Credit Facilities and New Share Repurchase Program (November 10th, 2016)

ALBANY, N.Y., Nov. 09, 2016 (GLOBE NEWSWIRE) – AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it has entered into a new credit facility and repaid and terminated its existing credit facilities. The new credit facility will further strengthen AngioDynamics’ capital structure and provide greater flexibility to make investments that support its growth strategy. In addition, AngioDynamics today announced that its Board of Directors has authorized a repurchase of up to $25 million of the Company’s common stock.

Angiodynamics Inc – CREDIT AGREEMENT dated as of November 7, 2016 among ANGIODYNAMICS, INC. The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent BANK OF AMERICA, N.A. and KEYBANK NATIONAL ASSOCIATION as Co-Syndication Agents and SUNTRUST BANK as Documentation Agent JPMORGAN CHASE BANK, N.A., MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED and KEYBANK NATIONAL ASSOCIATION as Joint Bookrunners and Joint Lead Arrangers (November 10th, 2016)

CREDIT AGREEMENT (this “Agreement”) dated as of November 7, 2016 among ANGIODYNAMICS, INC., the LENDERS from time to time party hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent, BANK OF AMERICA, N.A. and KEYBANK NATIONAL ASSOCIATION, as Co-Syndication Agents and SUNTRUST BANK, as Documentation Agent.

Angiodynamics Inc – CHANGE IN CONTROL AGREEMENT (October 5th, 2016)

THIS CHANGE IN CONTROL AGREEMENT (the “Agreement”), is made effective as of August 18, 2016 between AngioDynamics, Inc., a Delaware corporation (the “Company”), and Michael C. Greiner, an individual resident of the State of New York (“Executive”).